Estrella Immunopharma (ESLA) Research & Development (2022 - 2026)
Estrella Immunopharma (ESLA) posted quarterly Research & Development of $1.4 million for Q1 2026, down 0.7% year-over-year from $1.4 million in Q1 2025, and up 5409.86% quarter-over-quarter from $25414.0 in Q4 2025.
Estrella Immunopharma (ESLA) Research & Development (2022 - 2026) Analysis & Trends
Estrella Immunopharma (ESLA) has reported Research & Development for 5 consecutive years, with $1.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 0.7% year-over-year to $1.4 million; the TTM figure through Mar 2026 stood at $10.2 million (down 28.08% YoY), while the FY2025 annual figure was $10.2 million, up 59.92% from the prior year.
- Research & Development rose to $1.4 million in Q1 2026 per ESLA's latest filing, from $25414.0 in the prior quarter.
- Across five years, Research & Development topped out at $6.4 million in Q3 2024 and bottomed at $25000.0 in Q1 2024.
- Historically, Research & Development has averaged $2.3 million across 5 years, with a median of $2.6 million in 2022.
- On a YoY basis, Research & Development climbed as much as 5540.75% in 2025 and fell as far as 99.12% in 2025.
- Estrella Immunopharma's Research & Development stood at $2.6 million in 2022, then slumped by 97.11% to $75459.0 in 2023, then soared by 3743.15% to $2.9 million in 2024, then plunged by 99.12% to $25414.0 in 2025, then soared by 5409.86% to $1.4 million in 2026.
- Business Quant data shows ESLA's Research & Development at $1.4 million in Q1 2026, $25414.0 in Q4 2025, and $4.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Estrella Immunopharma | 32.24 Mn | 32.10 Mn | - | 1.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.40 Mn |
| Mar 31, 2026 | 1.40 Mn |
| Dec 31, 2025 | 25,414.00 |
| Sep 30, 2025 | 4.15 Mn |
| Jun 30, 2025 | 4.66 Mn |
| Mar 31, 2025 | 1.41 Mn |
| Dec 31, 2024 | 2.90 Mn |
| Sep 30, 2024 | 6.38 Mn |
| Jun 30, 2024 | 3.55 Mn |
| Mar 31, 2024 | 25,000.00 |
| Dec 31, 2023 | 75,459.00 |
| Sep 30, 2023 | 483,466.00 |
| Mar 31, 2023 | 2.62 Mn |
| Dec 31, 2022 | 2.61 Mn |
| Sep 30, 2022 | 2.61 Mn |